Regulatory pressure from the FDA and CMS presents a significant headwind for Novo Nordisk (NVO), making it a less attractive investment for growth. A recent FDA warning letter regarding Wegovy marketing highlights the immediate risk and potential for limited top-line growth. In contrast, Hims & Hers Health (HIMS) is positioned as a more investable company due to its telehealth model that currently avoids direct regulatory scrutiny. HIMS's focus on general wellness and longevity allows for more flexible marketing compared to traditional pharmaceutical companies. Investors should consider the significant advantage telehealth platforms have over heavily regulated "Big Pharma" stocks.

Novo Nordisk (NVO)

• Novo Nordisk recently received a warning letter from the FDA regarding its marketing practices for the weight-loss drug Wegovy.
• The FDA took issue with marketing phrases like "meet wegovy pill" and "live lighter by losing weight," which the podcast host considers to be basic marketing.
• The letter included a significant threat: Novo Nordisk must provide a plan to discontinue the ads or a plan to cease distribution of Wegovy within 15 days. This highlights the immense power the FDA holds over the company.
• The host argues that this heavy regulation is an "impediment to high growth" because it forces marketing to be "boring" and restricts the company's ability to grow its top line.
• Beyond the FDA, Novo Nordisk also has to deal with the Center for Medicare Services (CMS), which determines reimbursement eligibility. A negative decision from CMS would be a "second hurt to your business."
• The host believes that due to these dual regulatory pressures from the FDA and CMS, "Big Pharma should trade at a discount," and it's "even worse for Novo."

Takeaways

• Bearish Sentiment: The host views NVO as a "low-velocity business" due to the strict regulatory environment. The constant threat of regulatory action from the FDA and CMS creates significant risk and limits growth potential.
• Investment Thesis Risk: For a high-growth investor, the host considers NVO to be "less investable" compared to companies with less regulatory oversight. The regulatory hurdles take away management's attention and resources that could be used for growth.
• Valuation: The discussion suggests that companies like NVO, which are heavily dependent on regulators who are perceived as "anti-business," should be valued at a discount to account for this risk.

Hims & Hers Health, Inc. (HIMS)

• The host contrasts HIMS with Novo Nordisk, suggesting HIMS is in a much better position from a regulatory standpoint.
• HIMS is believed to have an "easier time advertising" because its ads are very general and do not promote specific, named drugs. Instead, they promote an app and tell a broader story about longevity and wellness.
• This general approach makes HIMS "less of a target for the FDA."
• The company's focus on longevity may not even fall under the FDA's current purview, as the host notes that longevity is not widely considered a formal field of medicine yet.

Takeaways

• Bullish Sentiment: The host views HIMS as "much more investable" for a high-growth investor. Its business model is less constrained by the strict regulations that hamper traditional pharmaceutical companies.
• Competitive Advantage: HIMS's ability to market more freely and directly to consumers without the same level of FDA scrutiny as a company like Novo Nordisk is a significant advantage.
• Potential Risk Factor: A key risk for HIMS would be if the FDA decides to take a "very strong stance" on regulating peptides or the longevity space in the future. This would make the business "less attractive" by subjecting it to the same growth-limiting rules as pharma companies.

General Investment Themes

• Regulatory Risk (FDA & CMS): The central theme is that heavy regulation from powerful agencies like the FDA and CMS creates a "low-velocity" business environment that stifles growth.
  • This is compared to the dynamic between Coinbase (COIN) and the SEC before the regulator became more "pro-crypto." A hostile regulator makes the entire sector less appealing for investment.
• Pharma vs. Telehealth Platforms: The transcript presents a clear preference for telehealth platforms (HIMS) over traditional "Big Pharma" (NVO) for growth-oriented investors. The telehealth model is seen as more agile and less encumbered by regulations.
• Longevity as a Sector: The "longevity" space is identified as the "next stage of medicine."
  • Currently, it exists in a regulatory gray area, which is a benefit for companies operating within it.
  • However, there is a risk of a "regulatory takeover" by the FDA, which would make stocks in this sector "less appealing."